Group items matching

in title, tags, annotations or url

Professional translators recreate texts, not simply matching word-for-word, but understanding the underlying meaning, purpose, and interpretation of the original language, and reproduce it using appropriate terminology and structure to ensure there is no potential for misunderstanding. An experienced technical translator addresses conventions to ensure the meaning of the information is preserved, using medical expertise and quality review processes to adapt documentation to meet the needs of patients, medical practitioners, and peers. Attention to detail is fundamental to medical translations and a non-technical translation is an unacceptably high risk for any organisation involved in publishing or circulating medical information of any kind. WHAT IS MEDICAL TRANSLATION? Medical translation is a technical process where capable translators reproduce content or documentation used anywhere in the medical industry, including psychiatry, systematic reviews, tuition and training, patient communications for pharmaceutical translation services. Important clinical trial translations can include labelling, prescriptions, medical devices and patient records, with millions of medicines and treatments used globally and written in multiple languages. Qualified medical translators must have exceptional linguistic skills but also a thorough understanding of medical sciences in all the native languages concerned. However, the complexity of translating one label or one document into several languages can mean that organisations may assume a simple translation is sufficient - when it is anything but!

Over the past two years, the Covid pandemic has resulted in a backlog of elective care within the NHS, with record numbers of patients on waiting lists across the UK. Despite efforts to catch up after the first wave, subsequent waves have put further strain on an already stretched NHS system. This has had a tremendous impact on many patients waiting for routine dermatology appointments and, while every effort has been made to see patients with suspected serious skin cancers within two weeks, this target is not always achieved. With rising waiting times, pharmacists are increasingly the first port of call for patients suffering with a broad range of skin problems. From acne and rosacea, eczema or psoriasis, to changing skin lesions or simple insect bites, pharmacists can give helpful advice, allowing some customers to find quick relief to their skin complaint in mild cases, while directing others to see their GP without delay. Below is some practical advice that pharmacists can give to their customers with commonly encountered skin complaints. Acne Acne is a common skin condition that not only affects teenagers but adults too. It is estimated that up to 40 per cent of women continue to suffer with acne into their adult years. Acne has been linked to an increased incidence of depression, anxiety and even suicidal ideation. Patients have reported feeling overlooked and often dismissed in their concerns by health care professionals. Unfortunately, these issues have been further compounded by delays in being seen and treated due to the ongoing Covid pandemic. Pharmacists are well placed to help acne patients choose the right skincare. This should consist of lightweight products, such as gel or milky cleansers, with moisturisers in serum, lotion or light cream preparations. Some acne suitable products are further labelled as non-comedogenic. Oil-based or occlusive preparations are best avoided. There are many good quality, non-comedogenic sun blocks suited

Alitam has announced that it has merged with clinical skills training provider MHRx to upskill UK pharmacists so that its chain of community pharmacies in the UK can diagnose and treat minor medical ailments "quickly and safely". This is a second merger deal announced by the group that has 100-plus pharmacies, just days after its merger with Pharmadoctor to "radically transform the UK and Ireland's community pharmacy sector" into a truly preventative healthcare system. Following the merger with MHRx, Alitam will now be providing a career development platform for its pharmacy teams, which also include nurses and other healthcare professionals. MHRx's training incorporates every aspect of general practice alongside relevant topics including making appropriate patient consultation records in line with NHS guidelines. This, Alitam believes, will allow community pharmacies to carry out formal diagnoses, formulate differential diagnosis plans, and perform full clinical examinations. According to the founder and CEO Feisal Nahaboo, mergers such as these will lead to "a healthcare revolution predicated on building the world's first truly preventative healthcare model".

Viveca Biomed has launched an innovative and clinically-proven bladder support device that offers women immediate relief from stress urinary incontinence (SUI) and provides community pharmacy contractors with a way to build a new consumer base, customer loyalty and sales margins. The product, named 'Contrelle Activgard', has already recorded millions of sales in Scandinavia over a decade. The company behind the UK launch is female healthcare business Viveca Biomed, founded in 2019 by Andrew Tasker who has spent 30+ years in senior roles within the OTC and pharma industry. Contrelle is manufactured, packed and distributed in the UK at Viveca Biomed's factory near Newcastle, with no outsourcing, and thus offering the best possible continuity of supply. Ahead of the launch, the company commissioned a large consumer lifestyle survey with 500 women over 40 years of age who experience bladder leaks, to reveal the extent of its detrimental impact. Contrelle Activgard is a safe, discrete, easy-to-use and highly effective, single-use vaginal device, designed to immediately prevent SUI rather than just deal with the leakage.

Anyone who has studied the finances of an independent pharmacy business knows that money is tight. In many cases, they are perilously close to failure. It's easy to assume they are retail businesses, cashing in on the higher public profile the sector has enjoyed during the pandemic years. But those have been mere words. Certainly, the pandemic represented a halcyon period for the profession. We engendered a feeling of normality, dependable and accessible to society. We played a substantive role in keeping people out of hospitals and giving the vulnerable the ability to live independently from their own homes for longer. We mobilised to smash flu vaccination records and deliver covid jabs. But despite the warm words of a new service based future and the incessant expressions of gratitude contractors desperately need the headroom to prepare, plan and invest. Platitudes, press releases and assurances of a bright clinical future are small comfort to what is needed and that's cash on the table. As the adage goes: "Talk is cheap, money buys houses." Cashflow crisis Since 2016, we have witnessed almost 650 pharmacies fall by the wayside. Some may have merged; the majority, however, have perished due to the relentless need for an increasing cashflow. It is cash, or rather the lack of it, which is killing independent pharmacies.

New GSK raised its 2022 forecast for the second time this year, after third-quarter earnings and sales topped estimates, continuing its strong start as a standalone prescription medicine and vaccine business since carving out its consumer health division Haleon. After years of underperformance relative to its peers and missing out on the lucrative market for the first set of COVID-19 vaccines, GSK has delivered a string of strong results. The latest is led by a record quarter for its blockbuster shingles vaccine Shingrix and higher-than-expected revenue from its COVID therapy, Xevudy. Having survived a revolt by activist investors Elliott and Bluebell last year, GSK's prospects have been boosted by clinical trial success, though concerns remain around U.S. litigation over heartburn drug Zantac. Thousands of lawsuits have been filed in the United States against a raft of drugmakers over allegations the heartburn drug contains a probable carcinogen.

The National Pharmacy Association (NPA) and BeWell are working together to help provide efficiencies and productivity that address the growing pressures within community pharmacy. BeWell's Pharmacy Management Platform provides robust solutions that include Patient Relationship Management, Omnichannel Communications and Engagement, Services and Bookings Management, access to patient records, NHS Login supported Patient Application, and repeat prescription capabilities for Pharmacy Website and Patient App that include integrations with Surgery Online Services. This single interoperable platform is also integrated with pharmacy PMRs, connecting back office and administrative functions with front-of-house digital patient experiences. In line with the NPA's vision, BeWell has taken a leading role in formulating a unique ecosystem of pharmacy partners uniting marketing agencies, PGD-based service providers, and delivery method partners - integrating their capabilities within the BeWell platform.

Northern Ireland's chief pharmaceutical officer paid a visit to a community pharmacy in Belfast on Monday (November 7) - marking the end of this year's Ask Your Pharmacist week, an annual public awareness campaign launched by the National Pharmacy Association. Cathy Harrison interacted with patients and staff in the pharmacy before recording a video to promote NI's 'Pharmacy First' service in which she described community pharmacies as "one of the front doors to the health service" with over 500 outlets located across the country. "In our community pharmacies you can always rely on friendly staff, medicines expertise, and walk-in access to face-to-face advice," she said. First launched in Scotland, the NHS Pharmacy First service enables patients to have a consultation with a pharmacist for advice on minor ailments. Ms Harrison also drew attention to community pharmacy's role in cancer awareness and helping people to quit smoking, as well as managing patients with urinary tract infections, in addition to playing their part in delivering Covid-19 and flu vaccinations.

Professor Harry McQuillan has said community pharmacists in the UK must change their focus from an 'accuracy of supply' to a 'safety of supply' model when it comes to dealing with patients. "The main take away message from tonight's lecture is for pharmacy professionals to really challenge themselves about whether they are focused on accuracy of supply or safety of supply," he said at this year's UCL School of Pharmacy Lecture in London on Thursday, 15 June. "For our community pharmacists it must be about safety, including prescribing, and ensuring patients and citizens get the maximum benefit from prescribed medicines. "To deliver this, we need to invest in our teams - harness technology and always be willing to take the next step in a more clinical future." The Chief Executive Office of Community Pharmacy Scotland, however, noted that at a time when the UK was grappling with an unprecedented national debt crisis exacerbated by severe cost of living and spiraling inflation, community pharmacy will need to make a "compelling case" of where the priority should be in the sector. Expanding on the financial woes of the country, he compared the current national debt of the UK, which stood at a staggering 270 percent of GDP in September 2022, with the previous record-breaking national debt of 250 per cent at the end of WWII.

Community pharmacies are well placed to play a role in preventing deaths from cardiovascular disease (CVD) said Director of NHS Services. The recent analysis by the British Heart Foundation (BHF) revealed that nearly 100,000 more people with cardiovascular disease than expected have died since the start of the pandemic in England. Latest figures show that the number of people waiting for time-sensitive cardiac care was at a record high of nearly 390,000 at the end of April in England. Average ambulance response times for heart attacks and strokes have consistently been above 30 minutes since the beginning of 2022, and in December 2022 they even breached 90 minutes. The target is 18 minutes, though the Government has set a new average target of 30 minutes over 2023/24. Director of NHS Services, Alastair Buxton, said: "It is concerning to hear that there have been tens of thousands of preventable deaths from cardiovascular disease (CVD) since the start of the COVID-19 pandemic. We share BHF's desire to see more action on preventing the causes of CVD and, subject to appropriate funding being in place, community pharmacy teams are well placed to play a role in this.

An experimental Alzheimer's drug developed by Eli Lilly and Co slowed cognitive decline by 35% in a late-stage trial, the company said on Wednesday, providing what experts say is the strongest evidence yet that removing sticky amyloid plaques from the brain benefits patients with the fatal disease. Lilly's drug, donanemab, met all goals of the trial, the company said. It slowed progression of Alzheimer's by 35% compared to a placebo in 1,182 people with early-stage disease whose brains had deposits of two key Alzheimer's proteins, beta amyloid as well as intermediate levels of tau, a protein linked with disease progression and brain cell death. The study also evaluated the drug in 552 patients with high levels of tau and found that when both groups were combined, donanemab slowed progression by 29% based on a commonly used scale of dementia progression known as the Clinical Dementia Rating Scale (CDR-SB). Using that scale, experts said Lilly's findings were roughly on par with Eisai Co Ltd and Biogen Inc's lecanemab, sold under the brand name Leqembi, which reduced cognitive decline by 27% in patients with early Alzheimer's in a study published last year. The results drove Lilly's shares to a record high, up more than 6% at $429.85. Dr. Ronald Petersen, an Alzheimer's researcher at Mayo Clinic, said Lilly's trial is the third to show removing amyloid from the brain slows progression of the disease, which could put to rest some lingering doubts about the benefits of drugs in the class and the amyloid-lowering theory. "It's modest, but I think it's real," he said of the benefit, "and I think it's clinically meaningful." Dr. Erik Musiek, a Washington University neurologist at Barnes-Jewish Hospital, said the efficacy looks as good or better than lecanemab.

The Pharmaceutical Services Negotiating Committee (PSNC)'s 2022 Pharmacy Advice Audit revealed that more than 1.2 million consultations a week - or 65 million a year - are now being carried out by community pharmacy teams in England. This is an increase from 2021, when the audit results suggested that in total pharmacies were providing 58 million consultations per year. PSNC has published the findings of the audit of over 4,000 community pharmacies carried out earlier this year. During the audit, 82,872 informal patient consultations were recorded, with the average pharmacy completing 19 consultations per day. This suggests that more than 1.2 million informal consultations are taking place in community pharmacies in England every week. The audit helped to quantify the number of informal referrals being made to pharmacies by GPs and NHS 111, with 7,774 informal patient referrals into pharmacy coming from these routes; grossed up to a national level that means 117,000 cases per week. These are all referrals that could and should have been made by the NHS Community Pharmacist Consultation Service (CPCS).

The Pharmacists' Defence Association has called on the Scottish government to end unnecessary pharmacy closures and introduce emergency regulations to force companies that operate Scotland's pharmacies to open on the days and hours they have agreed. It is concerned that decisions made by some health boards in Scotland have now allowed pharmacy owners to close their pharmacies on Saturdays. The PDA is worried that a pharmacy closure could have negative impact on patients and other parts of the NHS, including neighbouring pharmacies, addiction and mental health services, and minor injury and A&E units. The association claims that there are record numbers of registered pharmacists who are available to work and therefore a decision to close a pharmacy over staff shortages is misleading. "The business owners may claim there is a shortage of pharmacists, but when they actively cancel agreed hours of work it does not suggest there is a shortfall of workers," said the PDA, adding: "These business decisions often include closing their pharmacies at very short notice, even when pharmacists are available and willing to work."

Are you feeling overwhelmed about the MCAT? You're not alone! The MCAT is a challenging test that can feel daunting for even the best students. But don't worry, this article is here to help. This blog post will discuss six clever strategies that will help you pass the MCAT successfully. Follow these tips and you'll be on your way to achieving your dream score. ENROLL IN A PREP COURSE One of the first things you should do when preparing for the MCAT is to enroll in a prep course. Keep in mind that the right MCAT prep course will provide you with the resources and support you need to succeed. Additionally, it can help to take practice tests under simulated testing conditions. This will help you get used to the format of the test and reduce your anxiety on test day. In choosing a prep course, make sure to pick one that is reputable and has a good track record. You should also make sure that the course is affordable and offers a schedule that fits your needs. If possible, you can also take practice tests that are offered by the course. This way, you can get an idea of the type of questions that will be on the test. JOIN A STUDY GROUP Many people find that studying in a group is more effective than studying alone. When you join a study group, you'll have the opportunity to discuss difficult concepts with your peers. Additionally, you'll be able to hold each other accountable and stay on track with your studies. If you're not sure where to find a study group, ask your friends or classmates if they're interested in forming one. You can also check online forums or look for groups that have already been established.

NHS England has secured a deal for 'Dexcom ONE Real Time-Continuous Glucose Monitoring' device which will help type 1 diabetes patients to keep track of their glucose levels at all times without having to scan or take a finger prick test. Once the patients receive their starter pack - which will include information on the product and usage, a sensor and transmitter - from the hospital or GP surgery, they can go to the community pharmacy for their repeat prescription. The wearable arm gadget sends information to a mobile app and allows diabetes patients to keep track of their glucose levels. "Traditionally, continuous glucose monitors are more expensive than their flash monitor counterparts - which record glucose levels by scanning a sensor - but thanks to the NHS agreeing on a new cost-effective deal with manufacturers DEXCOM, they will now be available for NHS patients on prescription at a similar price," said NHS. Dexcom ONE Real Time-Continuous Glucose Monitoring, uses a sensor no bigger than a bottle cap that attaches to the arm for up to 10 days and measures glucose levels from just under the skin. The wider rollout of the technology will help diabetes patients manage their condition better - reducing hospitalisations and associated diabetic illnesses which will ultimately ease pressure off the NHS. Karen Baxter, vice president, UK & Ireland, Benelux, France and Spain at Dexcom: "The addition of Dexcom ONE to the NHS England drug tariff is enormous progress towards improving the choice of diabetes tech, providing an alternative to burdensome finger pricks and scanning.

The Pharmaceutical Services Negotiating Committee (PSNC) has challenged price concessions imposed by the Department of Health and Social Care (DHSC) on some of the medicines. It has raised concerns on the process for setting price concessions to senior government officials responsible for medicines supply, warning that the system is not working in the current environment from a community pharmacy contractor perspective. "When a new government takes over next week, this will be one of several urgent topics being raised by PSNC to new ministers, alongside the fuel price crisis, inflationary pressures and winter pressures on pharmacy businesses," said PSNC. The final update to August price concessions was announced yesterday taking the total concessions granted to a record 138 for August. PSNC said: "Of those, 99 were in line with PSNC requests, but prices for 39 lines were imposed by the Department of Health and Social Care (DHSC): those impositions do not match the purchase prices reported by contractors and the evidence of market prices which we passed on to DHSC. In particular, the final imposed prices of Apriprazole and Temazepam tablets has generated a lot of concern amongst contractors due to the large variation between their reimbursement prices and purchase prices during the month of August."

The General Pharmaceutical Council (GPhC) has published the results of the common registration assessment for aspiring pharmacists held on 2 November, 2023. An overall pass rate of 66 per cent was recorded this year, as compared to 56 per cent in 2022 and 61 per cent in 2021. A total of 1,067 candidates took the registration assessment, held jointly by the GPhC and Pharmaceutical Society of Northern Ireland (PSNI), of which 700 candidates cleared the assessment In 2022, 937 candidates sat the registration assessment of which 525 passed the assessment. Commenting on the results, GPhC Director of Education and Standards, Mark Voce, said: "I would like to congratulate all those who passed the November registration assessment and I look forward to them joining our register to continue to the next stage of their career. "There will be candidates who unfortunately did not pass the assessment. If this is the case, the information on our website outlines all the possible options of what to do next.

The National Health Service (NHS) retention programme has benefitted 23 NHS Trusts since it launched in April 2022, with thousands fewer staff leaving frontline roles. NHS data showed that 14,000 fewer staff left the service in the 12 months up to August 2023 (108,890) compared to 122,970 the year before. In a statement released on Thursday, the NHS England said it is expanding the pilot programme across the country to benefit 42 more NHS trusts. The programme is part of the NHS Long Term Workforce Plan ambition to retain up to 128,000 more staff over the next 15 years in addition to training record numbers of doctors, nurses and other healthcare professionals. Under this new initiative, NHS staff are being offered extra flexibility with working hours, clinical 'support squads' have been introduced to help menopausal women at work, and HR 'stay advocates' are designated to identify ways to keep staff on the brink of leaving.

The NHS England has developed and published a new vaccination strategy with an aim to increase national uptake of lifesaving vaccinations, and protect people against a range of diseases. Getting vaccinations will become easier than ever before, as the NHS App is being expanded with more additional features. Improved booking features such as new in-App bookings, invitation alerts and appointment notifications will make "booking a jab as easy as booking a cab," NHS leaders said. The NHS App overhaul will also include improved access to medical records, meaning users will be able to see their routine vaccination status over the coming months and years, making it easier for them to identify any missed vaccinations in their history.

Pharmacists globally are broadening their roles to support self-care, aiming to enhance patient health outcomes through increased contributions and proactive behaviours, according to a new report. However, significant barriers, including inadequate funding and limited access to patient records, impede the optimisation of self-care activities and outcomes improvement in this area, the International Pharmaceutical Federation (FIP) said in its report. The FIP report, titled 'Community Pharmacy Insights: Supporting the Need for Self-Care,' gathers insights from 238 respondents across 55 countries with the aim of providing evidence-based policy support for workforce development. Nearly all respondents (93.2 per cent) indicated that pharmacists should actively engage in providing self-care support, FIP said. Furthermore, 48.9 per cent supported the involvement of pharmacy technicians, while 39.2 per cent endorsed the participation of pharmacy assistants and other team members in offering self-care support.